Healthcare Sector Announces Acquisitions and Innovations - Research Report on Synta, Auxilium Pharmaceuticals, Accuray, and USANA Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 29, 2013 NEW YORK, November 29, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Accuray Incorporated (NASDAQ: ARAY), IPC The Hospitalist Company, Inc. (NASDAQ: IPCM), and USANA Health Sciences Inc. (NYSE: USNA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Synta Pharmaceuticals Corp. Research Report On November 21, 2103, Synta Pharmaceuticals Corp. (Synta) announced two publications with results demonstrating the activity of ganetespib in preclinical models and in a clinical treatment setting of triple-negative breast cancer (TNBC). Synta reported that ganetespib is a potent and selective inhibitor of the Hsp90 chaperone protein being evaluated in over 25 clinical trials, including a pivotal Phase 3 trial in non-small cell lung cancer. The Company informed that the results demonstrate the ability of ganetespib to down-regulate a number of key proteins involved in tumor growth and metastasis. According to Synta, results by Synta collaborators at Johns Hopkins University were published on-line in the Journal of Molecular Medicine and results by Synta scientists and collaborators at Dana-Farber Cancer Institute and Duke University were published in Clinical Cancer Research. Synta further reported that clinical activity was also observed along with a favorable toxicity profile in two TNBC patients treated with ganetespib monotherapy in the Company-sponsored ENCHANT-1 Phase 2 trial. The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/8ecc_SNTA -- Auxilium Pharmaceuticals Inc. Research Report On November 25, 2013, Auxilium Pharmaceuticals Inc. (Auxilium) announced that new and updated data were presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, which were the Phase 3 studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH) for the potential treatment of Peyronie's disease (PD). Auxilium reported that the data were presented at the Sexual Medicine Society of North America (SMSNA) 19th Annual Fall Scientific Meeting held November 21, 2013 to November 24, 2013 in New Orleans, LA. Adrian Adams, CEO and President of Auxilium, said, "Auxilium remains committed to addressing the unique and unmet health needs of men, and we continue to uncover new information that we believe supports our sBLA for XIAFLEX for the treatment of Peyronie's disease. We believe that, if approved by the FDA for the treatment of Peyronie's disease, XIAFLEX has the clinical profile to become an important option in a therapeutic area that currently has limited treatment options. We continue to work with the FDA as the agency reviews our sBLA." The Full Research Report on Auxilium Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/86a4_AUXL -- Accuray Incorporated Research Report On November 25, 2013, Accuray Incorporated (Accuray) announced continued momentum in global adoption of its CyberKnife and TomoTherapy Systems. Accuray reported that the CyberKnife and TomoTherapy Systems, to date, have been used in 40 countries to treat patients across the full spectrum of radiation oncology cases including prostate, lung, liver, breast, and head and neck cancers. According to the Company, Accuray's newest innovations are the CyberKnife M6 Series and the TomoTherapy H Series Systems treatment solutions. The CyberKnife M6 Series offers the ability to deliver high-quality, high-dose distributions that can be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life, while the TomoTherapy H Series facilitates interactive treatment planning for clinicians to make development of customized plans for a wide range of patients and disease types efficient. The Full Research Report on Accuray Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/36bf_ARAY -- IPC The Hospitalist Company, Inc. Research Report On November 26, 2013, IPC The Hospitalist Company, Inc. (IPC) announced that Judy Shumway, D.O., was recognized as one of the 2013 Top Hospitalists in the nation by ACP Hospitalist, a publication of the American College of Physicians. IPC reported that she was recognized in the November 2013 issue of the publication. Chairman and CEO Adam Singer said, "We are very proud that Dr. Shumway has been honored by ACP Hospitalist as one of the country's preeminent hospitalists. A natural-born leader and mentor to her practice, Dr. Shumway exemplifies IPC's core values of teamwork and professionalism. She works tirelessly to achieve superior performance, and she embodies the commitment of delivering the highest quality of care to her patients." The Full Research Report on IPC The Hospitalist Company, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d10a_IPCM -- USANA Health Sciences Inc. Research Report On November 26, 2013, USANA Health Sciences Inc. (USANA) announced that the Company has acquired full membership in the U.K. Direct Selling Association (DSA). USANA reported that the DSA represents the interests of businesses engaged in direct sales of consumer goods and is committed to guiding the direct selling industry. USANA's Deputy General Counsel of International Markets, Kevin McMurray, said, "The membership process required by the U.K. DSA is one of the most challenging vetting processes of any country-specific DSA I have ever encountered. It's not surprising they carry a very high degree of credibility in the direct selling industry." The Full Research Report on USANA Health Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/ee40_USNA ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
U.K. Bond Rating Affirmed at Aa1 by Moody’s After Scottish 'No' Vote
Healthcare Sector Announces Acquisitions and Innovations - Research Report on Synta, Auxilium Pharmaceuticals, Accuray, and
Press spacebar to pause and continue. Press esc to stop.